London, September 3, 2020- Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Nevada finding that Hikma's generic version of Vascepa ® 1 1 gm does not infringe any valid claim of six key Amarin-owned patents.
RNS Number: 8093 X Hikma Pharmaceuticals Plc 02 September 2020. LONDON, 2 September 2020- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that, in accordance with the Disclosure Guidance and Transparency Rules, we notify the market of the following:. Headquartered in the UK, we are a global company...
RNS Number: 4315 V Hikma Pharmaceuticals Plc 07 August 2020 London, 7 August 2020- Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2020.. ·Healthy balance sheet maintained, with net debt of $511 million and low leverage at 0.8 x net debt to core EBITDA 4,5.
RNS Number: 9718 U Hikma Pharmaceuticals Plc 03 August 2020. LONDON, 3 August 2020- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that, in accordance with the Disclosure Guidance and Transparency Rules, we notify the market of the following:. Headquartered in the UK, we are a global company with a...
RNS Number: 2464 T Hikma Pharmaceuticals Plc 16 July 2020 London, July 16, 2020- Hikma Pharmaceuticals PLC, will announce its interim financial results for the six months ended 30 June 2020 on Friday 7 August 2020.. A recording of the presentation will be available on the Company's website at www.hikma.com from 8:00am BST. Hikma will also hold a live Q&A...
RNS Number: 2852 S Hikma Pharmaceuticals Plc 07 July 2020 Hikma Finance USA LLC. Hikma Finance USA LLC announces today that it has published an offering circular dated 7 July 2020 in connection with the issuance of US $500,000,000 3.250 per cent. Guaranteed Notes due 2025 guaranteed by Hikma Pharmaceuticals PLC, Al Jazeerah Pharmaceutical Industries Ltd, Arab...
RNS Number: 1308 R Hikma Pharmaceuticals Plc 25 June 2020 TR-1: S tandard form for notification of major holdings. LONDON, 25 June 2020- Hikma Pharmaceuticals PLC announces as follows:. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1135 R Hikma Pharmaceuticals Plc 25 June 2020 Jochen Gann Resigns from the Board of Hikma. London, 25 June 2020- Hikma Pharmaceuticals PLC announces that, following the disposal of shares by Boehringer Ingelheim Invest GmbH and in accordance with the shareholder agreement between Hikma and BI, that Dr. Jochen Gann has resigned his directorship of...
RNS Number: 8326 Q FTSE Russell 23 June 2020. Hikma Pharmaceuticals: Shares in Issue and Investability Weight Change Changes in FTSE UK Index Series. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8100 Q Hikma Pharmaceuticals Plc 23 June 2020 TR-1: S tandard form for notification of major holdings. LONDON, 23 June 2020- Hikma Pharmaceuticals PLC announces as follows:. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7668 Q Hikma Pharmaceuticals Plc 23 June 2020 23 June 2020. Transaction in Own Shares and Total Voting Rights and Capital. Further to the announcements by Hikma and Boehringer Ingelheim Invest GmbH on 22 nd June 2020, Hikma today announces the Company has entered into arrangements to buy back approximately 12.8 million ordinary shares currently...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM AN...
RNS Number: 7089 Q Hikma Pharmaceuticals Plc 22 June 2020 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Buy back of up to approximately £295 million of shares from Boehringer Ingelheim. Concurrently with the...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM AN...
RNS Number: 6675 Q Hikma Pharmaceuticals Plc 22 June 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6672 Q Hikma Pharmaceuticals Plc 22 June 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6668 Q Hikma Pharmaceuticals Plc 22 June 2020 Hikma Pharmaceuticals PLC. Notification and public disclosure of transactions by persons discharging managerial responsibilities. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6755 O Hikma Pharmaceuticals Plc 02 June 2020. LONDON, 2 June 2020- In accordance with the UK Financial Conduct Authority's DTR 5.6. 1, Hikma Pharmaceuticals PLC notifies the market that as at 31 May 2020, its share capital consists of 243,169,353 ordinary shares with voting rights. Headquartered in the UK, we are a global company with a local presence...
Hikma Pharmaceuticals Plc (HIK.L) Announced that its wholly owned US subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa. In March 2020, the US District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision is currently being appealed. #HIK
RNS Number: 7388 N Hikma Pharmaceuticals Plc 22 May 2020 London, May 22, 2020- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, today announces that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration for its Icosapent Ethyl Capsules, 1 gm, the generic...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    241.47M

Company Profile

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma's operations are in the United States, the Middle East and North Africa Region and Europe.

Classification

Market Indices-
Watchlist